NCT04611802: A reported trial by Novavax
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT04611802 |
|---|---|
| Title | A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 27, 2020 |
| Completion date | April 10, 2023 |
| Required reporting date | April 10, 2026, midnight |
| Actual reporting date | July 14, 2025 |
| Date last checked at ClinicalTrials.gov | Aug. 25, 2026 |
| Days late | None |